study looked at androgen deprivation therapy in non-metastatic prostate cancer. This study found that the elimination of ADR post 5 years was associated with low recurrence. Relapse of increased PSA was associated with increasing Testosterone off of ADR. This study did not look at estrogens or androgen metabolites. Too short sided in its design.
Low Testosterone as defined via serum levels found to correlate with poor outcome in prostate cancer: positive margins, seminal vesicle invasion, and biochemical failure (ADR).
Another animal study finds Testosterone plays a role in bladder cancer development. The study used anti androgen and 5 alpha reductase inhibitor therapy to see if these add on therapies provided anything to ADR whether via castration or pituitary suppression--the answer was no. The authors concluded that Testosterone played more of a role with AR versus the more active 5alpha-DHT metabolite.
Group items tagged 
